This site is intended for health professionals only
Friday 24 May 2019
Share |

Topic: Gastroenterology

May 9, 2019
Familial chylomicronaemia syndrome is a debilitating disease caused by impaired function of the enzyme lipoprotein lipase, which causes high circulating levels of triglycerides in the body, leading to extreme abdominal pain and episodes of potentially fatal pancreatitis
Akcea Therapeutics and Ionis Pharmaceuticals have announced that Waylivra (volanesorsen) has received conditional marketing authorisation from the European Commission as an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.1
 
April 25, 2019
Non-alcoholic fatty liver disease is an area of extremely fast development of new treatments and careful attention and pharmaceutical expertise will be required to develop the treatment strategies to deal with the explosive growth of patients diagnosed with NAFLD and NASH
Non alcoholic fatty liver disease (NAFLD) is going to be the next big challenge for the health economy. 
 
A recent guidance by Public Health England1 reported the high obesity rate among England’s population: two thirds of adults, a quarter of 2-10-year-olds and one third of 11-15-year-olds are obese. The number of people who continue to have unhealthy and potentially dangerous weight is projected to rise and is of considerable public health concern.
 
March 26, 2019
Could dose de-escalation be an alternative strategy to decrease drug exposure, related risk, and treatment‐related costs while maintaining clinical remission in IBD?
The introduction of anti-tumour necrosis factor (anti-TNF) therapy in 1999 revolutionised the management of inflammatory bowel disease (IBD). The TAXIT trial introduced widely therapeutic drug monitoring (TDM) to tailor anti-TNF therapy and optimise the limited treatments options more effectively, particularly supporting decisions around non-response, loss of response and dose intensification.1 
 
March 20, 2019
One in four people with coeliac disease were previously misdiagnosed with IBS

With only 3% of British adults aware that the symptoms of IBS (irritable bowel syndrome) are also common symptoms of coeliac disease, Coeliac UK, is calling on greater awareness of the similarity of symptoms and urges anyone with IBS to ask their GP for a coeliac disease blood test, if they have not already had one.
 

March 18, 2019
44-week UNIFI data presented for the first time during plenary session at 14th Congress of the European Crohn’s and Colitis Organisation
Janssen has announced new data from the Phase III UNIFI maintenance study. 
 
March 4, 2019
Iron deficiency anaemia is frequently seen in inflammatory bowel disease and is difficult to treat, partly because many patients are intolerant to traditional oral iron therapies
Shield Therapeutics and Norgine have announced positive results from the AEGIS Head-to-Head (H2H) clinical trial, which compared Feraccru® (ferric maltol), a novel oral iron replacement therapy, to Ferinject® (ferric carboxymaltose (FCM)), a market-leading intravenously delivered iron replacement therapy.1
 
February 27, 2019
The largest study ever to look at why an expensive and commonly used group of drugs fails patients with Crohn’s disease has concluded that standardised drug doses are often too low

A UK wide collaboration led by the University of Exeter and the Royal Devon & Exeter NHS Foundation Trust, part-funded by Crohn’s & Colitis UK and Guts UK, and supported by the NIHR  has concluded that trials are needed to investigate whether early personalised dosing, guided by blood level monitoring, might help reduce the rate of treatment failure.
 

February 27, 2019
A genetic discovery could make treatment for Crohn’s disease and ulcerative colitis safer, by identifying patients who are at risk of potentially deadly drug side effects

A ground-breaking and large-scale NHS research collaboration, led by the University of Exeter and the Royal Devon & Exeter NHS Foundation Trust, has discovered a gene mutation that allows the identification of patients at risk of a drug side effect, allowing clinicians to tailor alternative treatments to these individuals.

 

October 26, 2018
Cannabis oil improves symptoms of Crohn’s despite no effect on gut inflammation

Cannabis oil significantly improves symptoms of Crohn’s disease despite having no effect on gut inflammation, according to new research.
 
The study, revealed at UEG Week conference in Vienna this week, found that cannabis produced clinical remission in up to 65% of individuals after eight weeks of treatment. However, it also found that it did this despite having no effect on gut inflammation, contrary to previous medical thinking.
 

July 11, 2018
The drug will be now available for dose optimisation in UC patients with a body weight of less than 80kg, who do not respond to induction therapy.

The European Commission (EC) has approved a label change for Simponi (golumumab) allowing early dose optimisation in patients with ulcerative colitis (UC).
 
The drug will be now available for dose optimisation in UC patients with a body weight of less than 80kg, who do not respond to induction therapy.
 

July 11, 2018
The drug will be now available for dose optimisation in UC patients with a body weight of less than 80kg, who do not respond to induction therapy.

The European Commission (EC) has approved a label change for Simponi (golumumab) allowing early dose optimisation in patients with ulcerative colitis (UC).
 
The drug will be now available for dose optimisation in UC patients with a body weight of less than 80kg, who do not respond to induction therapy.
 

April 11, 2018
<p>The Scottish Medicines Consortium (SMC) has accepted Shire&#39;s Revestive&reg; (teduglutide) for restricted use in children aged one and above with short bowel syndrome</p>

Global biotechnology company Shire has announced that the Scottish Medicines Consortium (SMC) has accepted its Revestive® (teduglutide) 5mg and 1.25mg for restricted use in the treatment of children aged one year and above with short bowel syndrome (SBS).

 

December 12, 2017
Globally, 694,000 people die from bowel cancer and 1.4 million people are diagnosed every year

Almost 332,000 people living in the UK will needlessly lose their lives to bowel cancer – a preventable, treatable and curable disease – between now and 2035 unless urgent action is taken to fill critical research gaps identified in a Bowel Cancer UK report ‘Finding the Key to the Cures: a plan to end bowel cancer by 2050’ launched today. If ignored, the scale of the issue will only grow larger.


The research has been published in the leading international academic journal, Gut.

November 2, 2017
CT-P13 shown to be comparable in efficacy and safety to reference infliximab in switched inflammatory bowel disease patients

Celltrion Healthcare and Pfizer have jointly announced data from the Phase III, randomised controlled, switching trial comparing CT-P13 and reference infliximab.

 

The data showed comparable efficacy and safety between all treatment groups (maintained and switched) in patients with moderate to severe Crohn’s disease (CD) up to one year.1

 

November 2, 2017
Late-breaking data demonstrate rapid improvement in patient-reported symptoms in patients intolerant or refractory to anti-TNF treatment

Janssen has presented new late-breaking data from UNITI-1 assessing Crohn's disease symptom improvement in patients during the first 2 weeks after an intravenous (IV) infusion dose of Stelara®(ustekinumab).1

 

The data presented at the 25th United European Gastroenterology Week (UEGW 2017) showed that patient-reported symptom improvement began as early as day 1 post ustekinumab IV infusion and was observed consistently at day 8 and beyond when compared with placebo.1

 

August 31, 2017
Truberzi® now funded by the NHS, becomes the first IBS-D treatment reviewed and recommended by NICE in a Technology Appraisal Guidance

Allergan has announced that the National Institute of Health and Care Excellence (NICE) has published Final Guidance, with the positive recommendation that Truberzi® (eluxadoline) be made available on the National Health Service for adults living with Irritable Bowel Syndrome with Diarrhoea (IBS-D).1

 

July 25, 2017
Novel compound belongs to an emerging form of treatments called peptide receptor radionuclide therapy, which involves targeting tumours with radiolabelled molecules that bind to specific receptors expressed by the tumour

Advanced Accelerator Applications S.A has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the marketing authorisation of lutetium (177Lu) oxodotreotide (Lutathera®) for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.
 

May 5, 2017
NICE recommendations are in line with the licensed indication for ustekinumab, speeding up access for patients with moderately to severely active Crohn’s disease

Janssen has announced that the National Institute for Health and Care Excellence (NICE) has recommended Stelara® (ustekinumab) in its Final Appraisal Determination (FAD) as a treatment option for adult patients with moderately to severely active Crohn’s disease, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF alpha inhibitor or have medical contraindications to such therapies.1
 

February 17, 2017
Results of the IM-UNITI Study Presented at the 12th Congress of ECCO

Janssen-Cilag International NV has announced  new two-year data from the ongoing IM-UNITI long-term extension (LTE) study evaluating the efficacy and safety of subcutaneous (SC) Stelara® (ustekinumab) in patients with moderate to severe Crohn’s disease.

 

The data presented at the 12th Congress of the European Crohn’s and Colitis Organisation (ECCO) showed that treatment with ustekinumab maintained clinical response and remission for up to two years with no new safety signals observed.1

January 18, 2017
Boehringer Ingelheim's adalimumab biosimilar candidate to Humira® has been accepted for regulatory review by the EMA and FDA
October 10, 2016
Calling all European pharmacists working in gastroenterology and/or hepatology (including IBD and viral hepatitis) to discuss and share practice, provide support in training needs and establish network opportunities.

October 10, 2016
Calling all European pharmacists working in gastroenterology and/or hepatology (including IBD and viral hepatitis) to discuss and share practice, provide support in training needs and establish network opportunities.

September 16, 2016
If approved, Stelara® will be the first interleukin (IL)-12/23 inhibitor licensed for Crohn’s disease

September 1, 2016
Publication of a pilot study by Coeliac UK shows early recognition of coeliac disease in community pharmacies

Coeliac UK the national charity for people with coeliac disease, announces the publication of an innovative project using community pharmacies to assist in finding patients with undiagnosed coeliac disease.

 

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine